Publications by authors named "Aida Di Stefano"
Article Synopsis
- The MITO-RT3/RAD trial was a Phase II study that evaluated the safety and effectiveness of stereotactic body radiotherapy (SBRT) for patients with oligometastatic ovarian cancer, focusing on those with lymph node disease.
- Results showed a significant improvement in complete response (CR) rates, with 77.9% of lesions achieving CR, and an overall clinical benefit rate of 99.6% from 135 enrolled patients with 249 lesions across various institutions.
- The trial indicated that SBRT has minimal toxicity, with 17% experiencing mild acute side effects, and it confirmed a strong correlation between CR and better progression-free survival (PFS)
Stereotactic Body Radiation Therapy for Oligoprogressive Ovarian Cancer Patients Treated During Poly(ADP-Ribose)-Polymerase Inhibitor Maintenance: Efficacy and Adverse Events From the Epimetheo Retrospective Study.
Int J Radiat Oncol Biol Phys
February 2025
Purpose: The aim of this observational, retrospective, multicenter study (Epimetheo) was to analyze the activity and the safety of stereotactic body radiation therapy (SBRT) during poly(ADP-ribose)-polymerase inhibitor (PARPi) maintenance in a series of oligometastatic ovarian cancer (OC) patients.
Methods And Materials: Patients treated with PARPi in maintenance setting received SBRT if oligometastatic progression occurred. Maintenance treatment was continued until the extensive progression of the disease.
Objective: To investigate the feasibility and determine the recommended pre-operative intensity-modulated radiotherapy (IMRT) dose of extended-field chemoradiation along with simultaneous integrated boost (SIB) dose escalation.
Methods: A radiation dose of 40 Gy over 4 weeks, 2 Gy/fraction, was delivered to the tumour and the lymphatic drainage (planning target volume, PTV3), which encompassed a volume larger than standard (common iliac lymphatic area up to its apex, in front of the L3 vertebra), concurrently with chemotherapy (cisplatin and 5-fluorouracil). Radiation dose was escalated to the pelvis (PTV2) and to the macroscopic disease (PTV1) with the SIB-IMRT strategy.